Trupanion's Q3 Net Income Soars 312% on Strong Revenue Growth
Ticker: TRUP · Form: 10-Q · Filed: 2025-11-06T00:00:00.000Z
Sentiment: bullish
Topics: Pet Insurance, Financial Results, Revenue Growth, Profitability, Earnings Per Share, Operating Income, Balance Sheet
Related Tickers: TRUP, PETS, WOOF
TL;DR
**TRUP is finally turning the corner on profitability, making it a strong buy as pet ownership continues to boom.**
AI Summary
Trupanion, Inc. reported a significant increase in net income for the three and nine months ended September 30, 2025. For the three months, net income surged to $5.873 million from $1.425 million in the prior year, a 312% increase. Revenue also grew, reaching $366.920 million for the quarter, up from $327.456 million in 2024, representing a 12.06% increase. For the nine-month period, the company swung to a net income of $13.803 million from a net loss of $11.289 million in the same period of 2024. Total revenue for the nine months increased by 12.03% to $1.062 billion from $948.377 million. Key business changes include increased investment in technology and development, up 24.6% to $9.887 million for the quarter, and a 19.87% rise in new pet acquisition expense to $21.946 million, indicating continued growth efforts. The company's balance sheet shows total assets growing to $880.173 million from $806.853 million at December 31, 2024, driven by increases in short-term investments and accounts receivable. Strategic outlook appears focused on continued expansion and operational efficiency, as evidenced by the improved profitability despite increased operating expenses.
Why It Matters
This strong performance signals Trupanion's ability to scale its pet insurance business profitably, which is crucial for investors in a competitive market. The significant increase in net income and revenue demonstrates effective execution of its growth strategy, potentially attracting more institutional investment. For employees, this financial health could mean job security and opportunities for growth within a thriving company. Customers benefit from a stable and expanding service provider, ensuring continued access to pet insurance. In the broader market, Trupanion's success could intensify competition in the pet insurance sector, potentially leading to innovation and better offerings across the industry.
Risk Assessment
Risk Level: medium — While net income is up significantly, the company's operating expenses, particularly 'new pet acquisition expense' at $21.946 million for the quarter, continue to be substantial. The 'reserve for veterinary invoices' also increased to $53.972 million from $51.635 million, indicating ongoing claims liabilities. The company also carries long-term debt of $113.790 million, which, while decreasing, still represents a financial obligation.
Analyst Insight
Investors should consider initiating or increasing positions in TRUP, given the strong swing to profitability and consistent revenue growth. Monitor the efficiency of new pet acquisition expenses and the management of veterinary invoice reserves, as these are key to sustained profitability.
Financial Highlights
- revenue
- $1.062B
- operating Margin
- 0.63%
- total Assets
- $880.173M
- total Debt
- $113.790M
- net Income
- $13.803M
- eps
- $0.32
- gross Margin
- 17.58%
- cash Position
- $154.773M
- revenue Growth
- +12.03%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Total Revenue | $1.062B | +12.03% |
Key Numbers
- $5.873M — Net Income (Q3 2025) (Increased 312% from $1.425M in Q3 2024)
- $366.920M — Revenue (Q3 2025) (Increased 12.06% from $327.456M in Q3 2024)
- $13.803M — Net Income (YTD Q3 2025) (Swing from a $11.289M net loss in YTD Q3 2024)
- $1.062B — Revenue (YTD Q3 2025) (Increased 12.03% from $948.377M in YTD Q3 2024)
- $0.14 — Basic EPS (Q3 2025) (Up from $0.03 in Q3 2024)
- $0.32 — Basic EPS (YTD Q3 2025) (Swing from $(0.27) in YTD Q3 2024)
- $21.946M — New Pet Acquisition Expense (Q3 2025) (Increased 19.87% from $18.308M in Q3 2024)
- $880.173M — Total Assets (Sept 30, 2025) (Increased from $806.853M at Dec 31, 2024)
- $53.972M — Reserve for Veterinary Invoices (Sept 30, 2025) (Increased from $51.635M at Dec 31, 2024)
- $113.790M — Long-term Debt (Sept 30, 2025) (Decreased from $127.537M at Dec 31, 2024)
Key Players & Entities
- TRUPANION, INC. (company) — Registrant for 10-Q filing
- SEC (regulator) — Securities and Exchange Commission
- FASB (regulator) — Financial Accounting Standards Board
- $5.873 million (dollar_amount) — Net income for three months ended September 30, 2025
- $1.425 million (dollar_amount) — Net income for three months ended September 30, 2024
- $366.920 million (dollar_amount) — Revenue for three months ended September 30, 2025
- $13.803 million (dollar_amount) — Net income for nine months ended September 30, 2025
- $11.289 million (dollar_amount) — Net loss for nine months ended September 30, 2024
- $1.062 billion (dollar_amount) — Revenue for nine months ended September 30, 2025
- $21.946 million (dollar_amount) — New pet acquisition expense for three months ended September 30, 2025
FAQ
What were Trupanion's net income and revenue for the three months ended September 30, 2025?
Trupanion, Inc. reported a net income of $5.873 million for the three months ended September 30, 2025, a significant increase from $1.425 million in the same period of 2024. Revenue for the quarter reached $366.920 million, up from $327.456 million in the prior year.
How did Trupanion's year-to-date financial performance compare to the previous year?
For the nine months ended September 30, 2025, Trupanion achieved a net income of $13.803 million, a substantial improvement from a net loss of $11.289 million in the same period of 2024. Total revenue for this period increased by 12.03% to $1.062 billion from $948.377 million.
What were the key drivers of Trupanion's increased operating expenses?
Key drivers of increased operating expenses for Trupanion included a 24.6% rise in technology and development expenses to $9.887 million for the three months ended September 30, 2025, and a 19.87% increase in new pet acquisition expense to $21.946 million for the same period.
What is Trupanion's current cash and investment position?
As of September 30, 2025, Trupanion had cash and cash equivalents of $154.773 million and short-term investments totaling $193.761 million. This represents a slight decrease in cash and cash equivalents from $160.295 million at December 31, 2024, but an increase in short-term investments from $147.089 million.
How has Trupanion's debt changed over the past nine months?
Trupanion's long-term debt decreased to $113.790 million as of September 30, 2025, from $127.537 million at December 31, 2024. The current portion of long-term debt also decreased to $750 thousand from $1.350 million.
What is the basic and diluted earnings per share for Trupanion?
For the three months ended September 30, 2025, Trupanion reported basic earnings per share of $0.14 and diluted earnings per share of $0.13. For the nine months ended September 30, 2025, both basic and diluted earnings per share were $0.32.
What are the primary risks Trupanion highlights in its filing?
Trupanion highlights that forward-looking statements are subject to risks, uncertainties, and assumptions, including those discussed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The company operates in a very competitive and rapidly changing environment, with new risks emerging over time.
What new accounting pronouncements might impact Trupanion?
Trupanion is evaluating the impact of ASU 2023-09 (income tax disclosures, effective after December 15, 2024), ASU 2024-03 (expense category disclosures, effective after December 15, 2026), and ASU 2025-06 (software costs, effective after December 15, 2027).
How many shares of common stock does Trupanion have outstanding?
As of October 30, 2025, Trupanion had approximately 43,198,164 shares of its common stock outstanding. The weighted average shares of common stock outstanding for diluted EPS for the three months ended September 30, 2025, was 43,562,132.
What is Trupanion's business model?
Trupanion, Inc. provides medical insurance for cats and dogs in the United States, Canada, and certain countries in Continental Europe. It uses a data-driven, vertically-integrated approach to develop and offer high-value medical insurance products, priced to account for each pet's unique characteristics and coverage level.
Risk Factors
- Veterinary Invoice Expense Volatility [high — operational]: Veterinary invoice expense, the largest cost component at $766.157 million for the nine months ended September 30, 2025, increased by 8.9% year-over-year. Fluctuations in veterinary care costs and utilization rates can significantly impact profitability.
- Increasing New Pet Acquisition Costs [medium — operational]: New pet acquisition expense rose by 19.87% to $21.946 million for Q3 2025 and 17.45% year-to-date to $62.305 million. While indicative of growth efforts, sustained increases without corresponding revenue growth could pressure margins.
- Technology and Development Investment [medium — operational]: The company increased investment in technology and development by 24.6% to $9.887 million for Q3 2025. While strategic for future growth, these investments represent a significant operating expense that needs to translate into long-term competitive advantages.
- Interest Expense [low — financial]: Interest expense was $2.790 million for Q3 2025 and $9.683 million for the nine months ended September 30, 2025. While down from the prior year, the company's debt levels and associated interest costs remain a factor in net income.
- Insurance Regulatory Environment [medium — regulatory]: As an insurance provider, Trupanion operates within a complex and evolving regulatory landscape across various jurisdictions. Changes in regulations related to pricing, coverage, or consumer protection could impact business operations and profitability.
Industry Context
The pet insurance industry continues to experience robust growth, driven by increasing pet humanization and rising veterinary care costs. Trupanion operates in a competitive landscape with other established players and emerging insurtech companies. Key trends include the adoption of technology for claims processing and customer engagement, as well as a focus on preventative care and wellness plans.
Regulatory Implications
Trupanion operates under state-specific insurance regulations in the U.S. and similar frameworks internationally. Compliance with these regulations, including those related to solvency, consumer protection, and claims handling, is critical. Changes in regulatory requirements could necessitate adjustments to business practices or product offerings.
What Investors Should Do
- [object Object]
- [object Object]
- [object Object]
- [object Object]
Key Dates
- 2025-09-30: End of Q3 2025 — Reported significant net income growth and revenue increase, demonstrating improved profitability and continued market expansion.
- 2025-09-30: Balance Sheet Date — Total assets grew to $880.173 million, driven by increases in short-term investments and accounts receivable, indicating asset growth and liquidity.
- 2024-12-31: End of Fiscal Year 2024 — Provided the comparative balance sheet figures, showing a baseline for asset growth and debt reduction.
Glossary
- Veterinary invoice expense
- The cost incurred by Trupanion to reimburse policyholders for veterinary treatments covered under their pet insurance policies. (This is the largest single expense category, directly impacting the company's gross margin and overall profitability. Its growth rate is a key indicator of underwriting performance and healthcare cost trends.)
- New pet acquisition expense
- Costs associated with marketing, sales, and onboarding new pet insurance policyholders. (This expense reflects the company's investment in growth. A rising trend indicates aggressive customer acquisition efforts, which need to be balanced against customer lifetime value.)
- Stock-based compensation expense
- The expense recognized for equity awards granted to employees and directors, such as stock options or restricted stock units. (This is a non-cash expense that is included in various operating cost categories. Understanding its allocation helps in analyzing the true operating performance of different segments.)
- Reserve for Veterinary Invoices
- An estimate of the amount of money the company expects to pay for veterinary services for claims that have been incurred but not yet paid. (This liability on the balance sheet is crucial for assessing the company's ability to meet its future payment obligations for services rendered.)
Year-Over-Year Comparison
Trupanion has demonstrated a significant turnaround in profitability, swinging from a net loss of $11.289 million in the first nine months of 2024 to a net income of $13.803 million for the same period in 2025. This improvement is accompanied by a consistent revenue growth of approximately 12% year-over-year for both the quarter and the year-to-date period. While operating expenses, particularly in technology and new pet acquisition, have increased, the company has managed to improve its operating income and net income, suggesting enhanced operational efficiency and pricing power. The balance sheet shows growth in total assets, supported by increased investments and receivables, while long-term debt has been reduced, indicating a strengthening financial position.
Filing Stats: 4,643 words · 19 min read · ~15 pages · Grade level 15.7 · Accepted 2025-11-06 17:02:53
Key Financial Figures
- $0.00001 — ange on which registered Common stock, $0.00001 par value per share TRUP The Nasdaq Sto
Filing Documents
- trup-20250930.htm (10-Q) — 1586KB
- ex311q32025.htm (EX-31.1) — 9KB
- ex312q32025.htm (EX-31.2) — 9KB
- ex321q32025.htm (EX-32.1) — 4KB
- ex322q32025.htm (EX-32.2) — 4KB
- 0001371285-25-000250.txt ( ) — 7243KB
- trup-20250930.xsd (EX-101.SCH) — 31KB
- trup-20250930_cal.xml (EX-101.CAL) — 49KB
- trup-20250930_def.xml (EX-101.DEF) — 201KB
- trup-20250930_lab.xml (EX-101.LAB) — 562KB
- trup-20250930_pre.xml (EX-101.PRE) — 400KB
- trup-20250930_htm.xml (XML) — 1151KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements (unaudited)
Item 1. Financial Statements (unaudited) 1
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 20
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 41
Controls and Procedures
Item 4. Controls and Procedures 41
- OTHER INFORMATION
PART II - OTHER INFORMATION
Legal Proceedings
Item 1. Legal Proceedings 42
Risk Factors
Item 1A. Risk Factors 42
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 42
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 43
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 43
Other Information
Item 5. Other Information 43
Exhibits
Item 6. Exhibits 44
Signatures
Signatures 45 Note About Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and Section 27A of the Securities Act of 1933, as amended ("Securities Act"). All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans and our objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "potentially," "estimate," "target," "continue," "anticipate," "intend," "could," "would," "project," "plan" and "expect," and similar expressions that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation, those discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission on February 27, 2025, in particular the risk factors discussed under the heading "Risk Factors" in Part I, Item 1A. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements TRUPANION, INC. Condensed Consolidated Statements of Operations (in thousands, except share data) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenue $ 366,920 $ 327,456 $ 1,062,452 $ 948,377 Cost of revenue: Veterinary invoice expense (1) 263,127 238,814 766,157 703,485 Other cost of revenue (1) 43,739 39,263 130,311 119,017 Total cost of revenue 306,866 278,077 896,468 822,502 Operating expenses: Technology and development (1) 9,887 7,933 26,545 23,083 General and administrative (1) 18,311 16,977 58,325 46,903 New pet acquisition expense (1) 21,946 18,308 62,305 53,025 Depreciation and amortization 4,051 4,381 11,804 12,542 Total operating expenses 54,195 47,599 158,979 135,553 Loss from investment in joint venture — ( 34 ) ( 305 ) ( 184 ) Operating income (loss) 5,859 1,746 6,700 ( 9,862 ) Interest expense 2,790 3,820 9,683 11,071 Other (income), net ( 3,530 ) ( 3,538 ) ( 18,684 ) ( 9,601 ) Income (loss) before income taxes 6,599 1,464 15,701 ( 11,332 ) Income tax (benefit) expense 726 39 1,898 ( 43 ) Net income (loss) $ 5,873 $ 1,425 $ 13,803 $ ( 11,289 ) Net income (loss) per share: Basic $ 0.14 $ 0.03 $ 0.32 $ ( 0.27 ) Diluted $ 0.13 $ 0.03 $ 0.32 $ ( 0.27 ) Weighted average shares of common stock outstanding: Basic 43,076,695 42,233,903 42,849,769 42,076,998 Diluted 43,562,132 42,822,505 43,550,326 42,076,998 (1) Includes stock-based compensation expense as follows: Veterinary invoice expense $ 677 $ 847 $ 2,221 $ 2,625 Other cost of revenue 585 554 1,679 1,561 Technology and development 1,705 1,259 4,326 3,774 General and administrative 4,971 4,125 14,546 11,435 New pet acquisition expense 1,561 1,555 6,013 5,743 See accompanying notes to the condensed consolidated financial statements. 1 TRUPANION, INC. Condensed Consolidated Statements of Comprehensive Income (Loss) (in thousands) (unaudited) Three Months Ended September 30, Ni